Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy

 Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy

Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy

Shots:

  • Post EU Approval, Udenyca has received FDA approval on basis of non-inferiority data including its PK, PD and immunogenicity in 600 healthy patients, receiving myelosuppressive CT having cancer
  • Udenyca novel pegfilgrastim-cbqv biosimilar, has received its EU approval on 21 Sep, 2018. In 2017, Pegfilgrastim had $4.5B sales worldwide
  • Udenyca (formerly CHS-1701) is a PEGylated growth colony-stimulating factor indicated to reduce chances of infection by febrile neutropenia

Click here to read full press release/ article | Ref: Reuters| Image: Marketing91

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post